Bristol-myers Squibb Compnay

Lalgudi S Harikrishnan

Muthoni G Kamau

Brian E Fink

Dharmpal S Dodd

Mark E Salvati

R Michael Lawrence

Wu Yang

James A Johnson

Heather J Finlay

Jennifer X Qiao

Yufeng Wang

Tammy C Wang

Yufen Zhao

Michael Matthew Miller

Ji Jiang

Zheming Ruan

Lan-Ying Qin

Robert Michael Borzilleri

John E Lloyd

Jacques Y Roberge

Jayakumar Sankara Warrier

Zulan Pi

Ashok Vinayak Purandare

Steven J Walker

Richard A Rampulla

Ashvinikumar V Gavai

Michael A Poss

James Aaron Balog

Wayne D Vaccaro

John S Tokarski

Weifang Shan

Bang-Chi Chen

Christopher P Mussari

David R Tortolani

Daniel O'Malley

Tram N Huynh

Libing Chen

Jianqing Li

Sören Giese

Gopikishan Tonukunuru

Peter Kinam Park

Mark George Saulnier

David Bertil Frennesson

Claude A Quesnelle

Xiao Zhu

Hasibur Rahaman

Matthew D Hill

Balaji Seshadri

The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Agonists of ROR GAMMAt

Cyclic dinucleotides as anticancer agents

The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Tricyclic compounds as anticancer agents

The invention relates generally to compounds that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2;R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. 

TGF beta receptor antagonists

The invention relates generally to compounds that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2; R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

TGF&#x3b2; receptor antagonist

The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Carbazole compounds useful as bromodomain inhibitors

The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using the compositions in the treatment of various disorders.

Compounds of formula Ia and Ib wherein A, B, C and Rare described herein.

Heterocyclic CETP inhibitors

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as Jak2 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Pyrrolotriazine kinase inhibitors

Compounds of formula Ia and Ib and wherein A, B, C and Rare described herein.

Growing community of inventors

Skillman, NJ, United States of America

Lalgudi S Harikrishnan